@article{rayer:hal-03551537, TITLE = {{Which second-line biologic after anti-TNF failure during Crohn's disease: Ustekinumab or vedolizumab, a multicentre retrospective study}}, AUTHOR = {Rayer, C. and Roblin, X. and Laharie, D. and Caron, Beno{\^i}t and Flamant, M. and Dewitte, M. and Fumery, Mathurin and Viennot, S. and Bourreille, A. and Pariente, B. and Siproudhis, L. and Peyrin-Biroulet, L. and Bouguen, G.}, URL = {https://u-picardie.hal.science/hal-03551537}, JOURNAL = {{Journal of Crohn's and Colitis}}, PUBLISHER = {{Elsevier - Oxford University Press}}, VOLUME = {14}, NUMBER = {1}, PAGES = {S547}, YEAR = {2020}, DOI = {10.1093/ecco-jcc/jjz203.793}, HAL_ID = {hal-03551537}, HAL_VERSION = {v1}, }